S D Solomon

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 380:1387-95. 2012
  2. ncbi request reprint Therapeutic approaches to diastolic dysfunction
    Rajesh Janardhanan
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Curr Hypertens Rep 11:283-91. 2009
  3. doi request reprint Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 119:530-7. 2009
  4. ncbi request reprint Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 369:2079-87. 2007
  5. ncbi request reprint Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02445, USA
    Circulation 110:2180-3. 2004
  6. doi request reprint Erythropoietic response and outcomes in kidney disease and type 2 diabetes
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 363:1146-55. 2010
  7. doi request reprint Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 122:985-92. 2010
  8. doi request reprint Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hypertension 55:241-8. 2010
  9. ncbi request reprint Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3411-9. 2005
  10. ncbi request reprint Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 150:257-62. 2005

Detail Information

Publications85

  1. doi request reprint The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 380:1387-95. 2012
    ..We assessed the efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), in patients with this disorder...
  2. ncbi request reprint Therapeutic approaches to diastolic dysfunction
    Rajesh Janardhanan
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Curr Hypertens Rep 11:283-91. 2009
    ....
  3. doi request reprint Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 119:530-7. 2009
    ..We compared the effect of aliskiren, the first orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combination on the reduction of LV mass in hypertensive patients...
  4. ncbi request reprint Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 369:2079-87. 2007
    ....
  5. ncbi request reprint Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02445, USA
    Circulation 110:2180-3. 2004
    ..We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program...
  6. doi request reprint Erythropoietic response and outcomes in kidney disease and type 2 diabetes
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 363:1146-55. 2010
    ..However, target-based strategies are confounded by each patient's individual hematopoietic response...
  7. doi request reprint Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 122:985-92. 2010
    ....
  8. doi request reprint Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hypertension 55:241-8. 2010
    ....
  9. ncbi request reprint Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3411-9. 2005
    ....
  10. ncbi request reprint Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 150:257-62. 2005
    ..Angiotensin-converting enzyme (ACE) inhibition attenuates ventricular remodeling and improves ventricular function in heart failure patients. Vasopeptidase inhibition has shown similar effects in experimental models...
  11. ncbi request reprint Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 352:2581-8. 2005
    ..We assessed the risk and time course of sudden death in high-risk patients after myocardial infarction...
  12. ncbi request reprint Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1511-4. 2004
    ..To investigate the hypothesis that prior angina pectoris confers protection from remodeling occurring after myocardial infarction (MI), we analyzed echocardiograms from the Healing and Early Afterload Reducing Therapy (HEART) trial...
  13. ncbi request reprint Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1482-7. 2007
    ....
  14. doi request reprint Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Eur Heart J 32:1227-34. 2011
    ....
  15. ncbi request reprint Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study
    S D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Ann Intern Med 134:451-8. 2001
    ..Nevertheless, recovery of ventricular function occurs in a significant proportion of patients after myocardial infarction, and modern reperfusion strategies have been associated with increased recovery of function...
  16. pmc Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:2104-13. 2008
    ..Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events...
  17. ncbi request reprint Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 114:1028-35. 2006
    ..Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal adenomas but have been associated with increased cardiovascular risk...
  18. ncbi request reprint Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1071-80. 2005
    ..Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern...
  19. ncbi request reprint Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 106:1251-5. 2002
    ..We used data from the Survival and Ventricular Enlargement (SAVE) echocardiographic substudy to test the hypothesis that diabetes was associated with increased LV enlargement after MI...
  20. ncbi request reprint Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:2687-93. 2007
    ..We assessed the association between albuminuria and the risks for death and cardiovascular events among patients with stable coronary disease...
  21. ncbi request reprint Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115, USA
    Circulation 114:26-31. 2006
    ..In the post-myocardial infarction setting, angiotensin-converting enzyme (ACE) inhibitors have been shown to be as effective in patients with impaired renal function as in those with preserved renal function...
  22. ncbi request reprint Cyclooxygenase-2 inhibitors and cardiovascular risk
    Scott D Solomon
    Noninvasive Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Cardiol 21:613-7. 2006
    ....
  23. ncbi request reprint Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    David Aguilar
    Cardiovascular Division, University of Texas Health Science Center, 6431 Fannin, MSB 1 246, Houston, TX 77030, USA
    Circulation 110:1572-8. 2004
    ..A prior diagnosis of diabetes mellitus is associated with adverse outcomes after acute myocardial infarction (MI), but the risk associated with a new diagnosis of diabetes in this setting has not been well defined...
  24. ncbi request reprint Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
    Nagesh S Anavekar
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 351:1285-95. 2004
    ..Renal failure is associated with one of the highest risks, but the influence of milder degrees of renal impairment is less well defined...
  25. ncbi request reprint Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience
    Kent Stephenson
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Heart Rhythm 4:308-13. 2007
    ....
  26. ncbi request reprint Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial
    M A Pfeffer
    Brigham and Women s Hospital, Boston, Mass, USA
    Circulation 95:2643-51. 1997
    ..Although ACE inhibitor therapy has been shown to reduce mortality in patients with acute myocardial infarction (MI), the optimal dose and the timing of its initiation have not been determined...
  27. ncbi request reprint Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study
    Jens Jakob Thune
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Soc Echocardiogr 19:1462-5. 2006
    ..Left ventricular (LV) ejection fraction (EF) and wall-motion index (WMI) have both been shown to be independent predictors of outcome after myocardial infarction (MI)...
  28. doi request reprint High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Rachel E Anderson
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 155:706-11. 2008
    ..We examined characteristics, cardiovascular outcomes, and the influence of risk factors on outcomes in young survivors of AMI...
  29. ncbi request reprint Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial
    Lakshminarayan Yerra
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Heart Rhythm 3:313-6. 2006
    ..The association of QRS duration with clinical outcomes in the post-myocardial infarction (MI) setting is less well defined...
  30. doi request reprint Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
    Anil Verma
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    JACC Cardiovasc Imaging 1:582-91. 2008
    ..This study sought to understand prognostic implications of increased baseline left ventricular (LV) mass and geometric patterns in a high risk acute myocardial infarction...
  31. ncbi request reprint Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial)
    Satish Kenchaiah
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 94:1-8. 2004
    ..10). We conclude that antecedent hypertension is associated with subsequent LV dilation in patients after acute myocardial infarction with LV systolic dysfunction...
  32. ncbi request reprint Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension
    Rajesh Janardhanan
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 152:246-52. 2006
    ....
  33. ncbi request reprint Celecoxib for the prevention of sporadic colorectal adenomas
    Monica M Bertagnolli
    Brigham and Women s Hospital, Boston, USA
    N Engl J Med 355:873-84. 2006
    ....
  34. ncbi request reprint Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02445, USA
    Circulation 112:3738-44. 2005
    ..The growing number of patients with preserved systolic function heart failure underscores the importance of understanding the relationship between ejection fraction and risk...
  35. ncbi request reprint Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction
    Jens J Thune
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Hypertension 51:48-54. 2008
    ..Whether aggressive antihypertensive treatment can reduce this risk remains unknown...
  36. ncbi request reprint A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study
    R Y L Zee
    Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215 1204, USA
    Clin Genet 61:21-5. 2002
    ....
  37. ncbi request reprint Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction
    Powell Jose
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Soc Nephrol 17:2886-91. 2006
    ..Monitoring serum creatinine in patients during the first few weeks after MI may help to identify those who are at highest risk and guide effective long-term therapeutic choices...
  38. doi request reprint Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both
    Sung Hee Shin
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 121:1096-103. 2010
    ..Mechanical dyssynchrony is considered an independent predictor for adverse cardiovascular outcomes in patients with heart failure. However, its importance as a risk factor after myocardial infarction is not well defined...
  39. ncbi request reprint The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study
    Anil Verma
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1238-45. 2007
    ..The purpose of this study was to determine whether alterations in cardiac structure or function contribute to the increased risk associated with renal impairment after myocardial infarction (MI)...
  40. ncbi request reprint Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Rajesh Janardhanan
    Division of Cardiology, Brigham and Women s Hospital, Boston, MA02115, USA
    Am Heart J 152:183-9. 2006
    ..It is not known, however, whether the extent of coronary artery disease (CAD) independently influences cardiovascular (CV) outcomes in these high-risk patients...
  41. ncbi request reprint Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function
    Maria Amigoni
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Eur Heart J 28:326-33. 2007
    ....
  42. doi request reprint Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study
    Alessandra Meris
    Cardiovascular Division, Brigham and Women s Hospital, MA, USA
    Eur Heart J 30:56-65. 2009
    ..To assess the relationship between left atrial (LA) size and outcome after high-risk myocardial infarction (MI) and to study dynamic changes in LA size during long-term follow-up...
  43. ncbi request reprint Right ventricular dysfunction and adverse outcome in patients with advanced heart failure
    Michael E Field
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Card Fail 12:616-20. 2006
    ....
  44. ncbi request reprint Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction
    Hasan Jilaihawi
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 91:723-6. 2003
  45. ncbi request reprint Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction
    Leonardo A M Zornoff
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 39:1450-5. 2002
    ..The aim of this study was to determine the prognostic value of right ventricular (RV) function in patients after a myocardial infarction (MI)...
  46. ncbi request reprint Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism
    Tudor Scridon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Cardiol 96:303-5. 2005
    ..Patients with elevated troponin and right ventricular enlargement are at significantly greater risk for death after PE than patients with only 1 or with neither adverse prognostic marker...
  47. pmc Predictors of heart failure in patients with stable coronary artery disease: a PEACE study
    Eldrin F Lewis
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circ Heart Fail 2:209-16. 2009
    ..The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction...
  48. ncbi request reprint Value of the electrocardiogram in predicting left ventricular enlargement and dysfunction after myocardial infarction
    Costantina Manes
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Med 114:99-105. 2003
    ..Predischarge ECG may be a useful tool for early identification of patients at risk of ventricular enlargement and persistent dysfunction following myocardial infarction...
  49. pmc Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction
    Ellen O Weinberg
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Cambridge, Mass 02139, USA
    Circulation 106:2961-6. 2002
    ..We identified an interleukin-1 receptor family member, ST2, as a gene markedly induced by mechanical strain in cardiac myocytes and hypothesized that ST2 participates in the acute myocardial response to stress and injury...
  50. ncbi request reprint Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging
    Andrew T Yan
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts 02115, USA
    J Cardiovasc Magn Reson 8:831-7. 2006
    ....
  51. doi request reprint Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
    Faisal Shamshad
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 160:145-51. 2010
    ..Myocardial rupture is a relatively rare and usually fatal complication of myocardial infarction (MI). Early recognition of patients at greatest risk of myocardial rupture provides an opportunity for early intervention...
  52. ncbi request reprint Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction
    S D Solomon
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 02115, USA
    J Cardiovasc Pharmacol 37:S31-4. 2001
    ..Recent clinical trials have shown that ACE inhibitors confer significant protection from ischemic events...
  53. doi request reprint Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial
    George V Moukarbel
    Division of Cardiovascular Diseases, Department of Internal Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Eur Heart J 30:2226-32. 2009
    ..Risk factors for GI bleeding in post- myocardial infarction (MI) patients have not been well defined. We sought to identify risk factors for GI bleeding in patients following MI...
  54. ncbi request reprint Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
    Akshay S Desai
    Department of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1959-66. 2007
    ..We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients...
  55. doi request reprint Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study)
    Nagesh S Anavekar
    Department of Cardiology, Austin Health, University of Melbourne, Melbourne, Australia
    Am J Cardiol 101:607-12. 2008
    ..53 (95% CI 1.24 to 1.88) increased risk of fatal and nonfatal CV outcomes. In conclusion, decreased right ventricular systolic function is a major risk factor for death, sudden death, HF, and stroke after MI...
  56. ncbi request reprint Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  57. ncbi request reprint Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction
    David Aguilar
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 43:2015-21. 2004
    ..We assessed the influence of alcohol intake on the development of symptomatic heart failure (HF) in patients with left ventricular (LV) dysfunction after a myocardial infarction (MI)...
  58. ncbi request reprint Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials
    Maria Tokmakova
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Curr Opin Cardiol 21:268-72. 2006
    ..This article will review the background and major clinical trials that have shaped this field over the past 15 years...
  59. doi request reprint A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
    Marc A Pfeffer
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2019-32. 2009
    ..Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested...
  60. ncbi request reprint Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience
    Nagesh S Anavekar
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Soc Echocardiogr 19:28-33. 2006
    ..The prognostic significance of MPI is less clear for cardiovascular (CV) events after myocardial infarction (MI) among individuals at high risk with depressed left ventricular (LV) systolic function...
  61. ncbi request reprint Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study
    Nagesh S Anavekar
    Cardiovascular Clinical Trials Unit, Austin Health, University of Melbourne, Melbourne, Australia
    Echocardiography 24:452-6. 2007
    ..Hence, quantitative estimation of RV function has proven difficult in clinical practice...
  62. doi request reprint Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Kidney Dis 54:59-69. 2009
    ....
  63. ncbi request reprint Left ventricular assessment in myocardial infarction: the VALIANT registry
    Adrian F Hernandez
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 165:2162-9. 2005
    ..How often echocardiography and cardiac catheterization are used to evaluate left ventricular (LV) function in patients with myocardial infarction (MI) and how they are associated with quality of care is unknown...
  64. doi request reprint Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus
    Nagesh S Anavekar
    Clinical Trials Unit, Austin Health, University of Melbourne, Melbourne, Australia
    Am J Cardiol 101:925-9. 2008
    ....
  65. ncbi request reprint Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Satish Kenchaiah
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 116:627-36. 2007
    ..However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality...
  66. ncbi request reprint Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: evidence from clinical trials
    George V Moukarbel
    Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Curr Heart Fail Rep 5:197-203. 2008
    ..Careful use of these agents is essential in avoiding clinically significant hypotension in the critical period...
  67. ncbi request reprint Variable impact of combining fatal and nonfatal end points in heart failure trials
    Hicham Skali
    Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 114:2298-303. 2006
    ..Longer-duration trials have a more predictable increase in events than short RCTs. Trial duration must be considered when composite end points are used during the design and interpretation of HF RCTs...
  68. doi request reprint Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Re
    Jonathan P Piccini
    Division of Cardiology, Department of Medicine, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 102:1427-32. 2008
    ..Unfortunately, beta blockers were underused acutely in patients with sustained VT/VF...
  69. ncbi request reprint A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene
    G Tanigawa
    Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115
    Cell 62:991-8. 1990
    ..In one kindred, an unequal crossover event during meiosis may have produced the alpha/beta cardiac MHC hybrid gene that is present in affected individuals. We conclude that mutations in the cardiac MHC genes can cause FHC...
  70. doi request reprint Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    Michael R MacDonald
    Glasgow Royal Infirmary, Glasgow, UK
    Eur Heart J 29:1377-85. 2008
    ..To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection fraction (EF) heart failure (HF)...
  71. ncbi request reprint Aldosterone antagonism and myocardial infarction: from animals to man and back
    Scott D Solomon
    J Am Coll Cardiol 42:1674-6. 2003
  72. ncbi request reprint Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials
    James B Young
    Division of Medicine, The Cleveland Clinic Foundation and Kaufman Center for Heart Failure, 9500 Euclid Avenue T 13, Cleveland, OH 44195, USA
    Circulation 110:2618-26. 2004
    ..CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program...
  73. ncbi request reprint Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study
    Mariya P Tokmakova
    Department of Cardiology, St George Hospital, Medical University Plovdiv, Plovdiv, Bulgaria
    Circulation 110:3667-73. 2004
    ..Future cardiovascular event rates and the relative response to therapy in persons with mild to moderate CKD are not well characterized...
  74. ncbi request reprint Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease
    T Christian H Mix
    Department of Development and Medical Affairs, Amgen Inc, Thousand Oaks, Calif, USA
    Am Heart J 149:408-13. 2005
    ....
  75. ncbi request reprint Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
    Karolina E Szummer
    Department of Cardiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur Heart J 26:2114-9. 2005
    ..We sought to assess the relative contribution of heart failure (HF) on admission for an acute myocardial infarction (MI) to the subsequent in-hospital stroke risk...
  76. ncbi request reprint Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiograph
    Roberto M Lang
    University of Chicago Hospitals, Chicago, IL, USA
    J Am Soc Echocardiogr 18:1440-63. 2005
  77. ncbi request reprint Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program
    Eileen O'Meara
    Western Infirmary, Glasgow, UK
    Circulation 113:986-94. 2006
    ..We wished to determine the prevalence of, potential mechanistic associations of, and clinical outcomes related to anemia in patients with heart failure and a broad spectrum of left ventricular ejection fraction (LVEF)...
  78. ncbi request reprint Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction
    Lars Køber
    Department of Cardiology, Non Invasive Lab, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    Eur J Heart Fail 8:591-8. 2006
    ....
  79. ncbi request reprint Celecoxib for the prevention of colorectal adenomatous polyps
    Nadir Arber
    Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    N Engl J Med 355:885-95. 2006
    ..Overexpression of cyclooxygenase 2 (COX-2) has been associated with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention...
  80. pmc Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy
    Gary F Mitchell
    Cardiovascular Engineering, Inc, Waltham, MA 02453, USA
    Hypertension 49:1271-7. 2007
    ....
  81. ncbi request reprint Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Tim Clayton
    Western Infirmary, Glasgow, Scotland, UK
    Circulation 115:3111-20. 2007
    ....
  82. ncbi request reprint Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an acute myocardial infarction
    Lisa M Mielniczuk
    Cardiology Division, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Congest Heart Fail 13:209-14. 2007
    ..77-1.65). Elevated LVEDP is common following myocardial infarction; however, it is not an independent predictor of subsequent HF risk. The variability in LVEDP is not fully explained by infarct size and atherosclerotic burden...
  83. ncbi request reprint Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
    Kevin L Thomas
    Duke Clinical Research Institute, Duke University Medical Center, Durham NC 27710, USA
    Am Heart J 155:87-93. 2008
    ....
  84. doi request reprint Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
    R A P Weir
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, United Kingdom Faculty of Medicine, University of Glasgow, United Kingdom
    Eur J Heart Fail 10:157-63. 2008
    ..The CHARM-Added trial describes the largest experience of using multiple inhibitors of the renin-angiotensin-aldosterone system (RAAS) together...
  85. ncbi request reprint Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials
    Inder S Anand
    Division of Cardiology, University of Minnesota Medical School and Veterans Administration Medical Center, Minneapolis, MN 55417, USA
    J Card Fail 8:S452-64. 2002
    ..Thus, to study the process of remodeling in practice and in clinical trials, we have relied on assessments and measurements derived from cardiac imaging tests...